OTCMKTS:BMXMF

bioMérieux Stock Forecast, Price & News

$108.75
+0.85 (+0.79 %)
(As of 06/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$107.91
$108.81
50-Day Range
$105.65
$137.09
52-Week Range
$105.65
$170.55
Volume6 shs
Average Volume166 shs
Market Capitalization$12.87 billion
P/E Ratio27.88
Dividend YieldN/A
Beta-0.2
30 days | 90 days | 365 days | Advanced Chart
Receive BMXMF News and Ratings via Email

Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter.


bioMérieux logo

About bioMérieux

bioMérieux S.A. develops and produces in vitro diagnostic solutions for private and hospital laboratories for the diagnosis of infectious diseases. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Headlines

bioMérieux (OTCMKTS:BMXMF) Reaches New 12-Month Low at $105.65
bioMérieux (OTCMKTS:BMXMF) Reaches New 12-Month Low at $105.65
June 18, 2021 |  americanbankingnews.com
bioMérieux (OTCMKTS:BMXMF) Reaches New 52-Week Low at $108.55
bioMérieux (OTCMKTS:BMXMF) Reaches New 52-Week Low at $108.55
June 11, 2021 |  americanbankingnews.com
Berenberg Bank Upgrades bioMérieux (OTCMKTS:BMXMF) to Hold
Berenberg Bank Upgrades bioMérieux (OTCMKTS:BMXMF) to Hold
June 11, 2021 |  americanbankingnews.com
bioMérieux (OTCMKTS:BMXMF) Hits New 12-Month Low at $109.03
bioMérieux (OTCMKTS:BMXMF) Hits New 12-Month Low at $109.03
June 4, 2021 |  americanbankingnews.com
bioMérieux (OTCMKTS:BMXMF) Trading 0.4% Higher
bioMérieux (OTCMKTS:BMXMF) Trading 0.4% Higher
June 1, 2021 |  americanbankingnews.com
bioMérieux - 2020 Financial Results
bioMérieux - 2020 Financial Results
March 23, 2021 |  finanznachrichten.de
bioMérieux - First-Half 2020 Results
bioMérieux - First-Half 2020 Results
September 29, 2020 |  finanznachrichten.de
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.63 out of 5 stars

Medical Sector

1398th out of 2,105 stocks

Private Households Industry

249th out of 381 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











bioMérieux (OTCMKTS:BMXMF) Frequently Asked Questions

Is bioMérieux a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bioMérieux in the last year. There are currently 2 sell ratings, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" bioMérieux stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMXMF, but not buy additional shares or sell existing shares.
View analyst ratings for bioMérieux
or view top-rated stocks.

What stocks does MarketBeat like better than bioMérieux?

Wall Street analysts have given bioMérieux a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but bioMérieux wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting bioMérieux?

bioMérieux saw a increase in short interest in May. As of May 14th, there was short interest totaling 604,100 shares, an increase of 23.3% from the April 29th total of 489,900 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is currently 6,041.0 days.
View bioMérieux's Short Interest
.

When is bioMérieux's next earnings date?

bioMérieux is scheduled to release its next quarterly earnings announcement on Wednesday, June 23rd 2021.
View our earnings forecast for bioMérieux
.

How has bioMérieux's stock been impacted by COVID-19?

bioMérieux's stock was trading at $91.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BMXMF shares have increased by 18.9% and is now trading at $108.75.
View which stocks have been most impacted by COVID-19
.

Who are bioMérieux's key executives?

bioMérieux's management team includes the following people:
  • Mr. Alexandre Merieux, Chairman & CEO (Age 47, Pay $1.3M)
  • Mr. Frederic Beseme, Employee Director & Head of CSR (Age 65, Pay $30.41k)
  • Mr. Guillaume Bouhours, Exec. VP of Purchasing and Information Systems & CFO (Age 45)
  • Mr. Pierre Boulud, Chief Operating Officer (Age 50)
  • Sylvain Morgeau, Investor Relations
  • Ms. Esther Wick, Exec. VP of Legal, Intellectual Property & Compliance
  • Ms. Valerie Leylde, Exec. VP of HR & Communications
  • Mr. François Lacoste, Exec. VP of R&D
  • Mr. Mark Miller, Exec. VP & Chief Medical Officer
  • Mr. Pierre Charbonnier, Exec. VP of Quality, Manufacturing & Supply Chain

Who are some of bioMérieux's key competitors?

What is bioMérieux's stock symbol?

bioMérieux trades on the OTCMKTS under the ticker symbol "BMXMF."

How do I buy shares of bioMérieux?

Shares of BMXMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bioMérieux's stock price today?

One share of BMXMF stock can currently be purchased for approximately $108.75.

How much money does bioMérieux make?

bioMérieux has a market capitalization of $12.87 billion and generates $3.56 billion in revenue each year. The company earns $461.95 million in net income (profit) each year or $3.90 on an earnings per share basis.

How many employees does bioMérieux have?

bioMérieux employs 12,000 workers across the globe.

What is bioMérieux's official website?

The official website for bioMérieux is www.biomerieux.com.

Where are bioMérieux's headquarters?

bioMérieux is headquartered at 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280.

How can I contact bioMérieux?

bioMérieux's mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company can be reached via phone at 33-4-78-87-20-00 or via email at [email protected]


This page was last updated on 6/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.